Calliditas Therapeutics AB (CALT)

NASDAQ: CALT · Delayed Price · USD
18.99
-0.56 (-2.86%)
At close: Jan 26, 2022 4:00 PM
19.84
0.85 (4.48%)
Pre-market:Jan 27, 2022 6:59 AM EST

Company Description

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.

The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy.

Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.

Calliditas Therapeutics AB
Calliditas Therapeutics AB Logo
CountrySweden
Founded2004
IPO DateJun 5, 2020
IndustryBiotechnology
SectorHealth Care
Employees65

Contact Details

Address:
Kungsbron 1
Stockholm, Stockholm 111 22
Sweden
Phone46 84 11 30 05
Websitecalliditas.se

Stock Details

Ticker SymbolCALT
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencySEK
IPO Price$19.50
CIK Code1795579

Key Executives

NamePosition
Renee Aguiar-LucanderChief Executive Officer
Fredrik JohanssonChief Financial Officer
Dr. Katayoun Welin-Berger Ph.D.Vice President of Operations
Dr. Johan Haggblad Ph.D.Chief Scientific Officer
Mikael WidellHead of Communications and IR
Jonathan A. SchurGroup General Counsel
Ann-Kristin MydeHead of Clinical Development and Vice President of Project Management
Andrew B. Udell B.Sc., M.B.A.President of North America
Dr. Krassimir MitchevHead of Medical Affairs
Dr. Richard S. Philipson M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jan 14, 202220-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]
Dec 16, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 18, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 2, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Sep 16, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Sep 14, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Aug 31, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Aug 20, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Aug 13, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Aug 12, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
View All SEC Filings